8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): September 2, 2025

    

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-33407	41-1458152
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2401 Elliott Avenue, Suite 320
Seattle, Washington		98121
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (206) 676-0900

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	CATX	NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 2, 2025, the Board of Directors (the “Board”) of Perspective Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominations and Corporate Governance Committee of the Board (the “Nominations Committee”), voted to increase the size of the Board from five to six directors (the “Director Increase”) and to appoint Maya Martinez-Davis as a member of the Board to fill the vacancy created by the Director Increase, in each case effective as of September 3, 2025 (the “Effective Date”). The Board also approved the appointment of Ms. Martinez-Davis as a member of the Compensation Committee of the Board and the Nominations Committee, in each case effective as of the Effective Date.

Ms. Martinez-Davis is eligible to participate in the Company’s Non-Employee Director Compensation Program, which provides for an annual cash retainer of $60,000 for her services as a director and an initial grant of 75,000 options to purchase shares of the Company’s common stock (provided that the grant date fair value of such grant may not exceed $450,000), which will vest in 36 equal monthly installments beginning on the date that is one month following the grant date, subject to her continued service through each such vesting date. The Company also expects Ms. Martinez-Davis to enter into the Company’s standard indemnification agreement for Company directors.

There is no arrangement or understanding between Ms. Martinez-Davis and any other person pursuant to which Ms. Martinez-Davis has been appointed as a director, and Ms. Martinez-Davis has no direct or indirect interest in any transaction, or any proposed transaction, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 7.01 Regulation FD Disclosure.

On September 3, 2025, the Company issued a press release announcing Ms. Martinez-Davis’s appointment to the Board as described in Item 5.02 of this Form 8-K and related matters. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release dated September 3, 2025.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			PERSPECTIVE THERAPEUTICS, INC.

Date:	September 3, 2025	By:	/s/ Johan (Thijs) Spoor
			Johan (Thijs) Spoor Chief Executive Officer

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

SEATTLE – September 03, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company’s Board of Directors, effective today.

Ms. Martinez-Davis currently serves as President of GSK’s U.S. Commercial business, a position she has held since September 2019. In that role, she leads a robust and complex business portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin America at Merck KGaA, from April 2018 to August 2019, and prior to that served as Senior Vice President and Head of Global Oncology for its biopharma business from January 2016 through March 2018. Prior to joining Merck, she worked at Pfizer, Inc., from 2003 to 2015 in the areas of oncology, vaccines and specialty portfolios, including over a decade in senior executive roles. In addition, Ms. Martinez-Davis served on the Board of Directors of Mirati Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of targeted oncology therapies, from 2018 until its acquisition by Bristol Myers Squibb in January 2024. Ms. Martinez-Davis holds an undergraduate degree from Saint Louis University and a Master’s in business leadership and marketing from the IE Business Institute in Madrid, Spain.

Lori Woods, Chairperson of Perspective, commented, “The Board and I are excited to welcome Maya and look forward to working with her as we continue to guide the Company towards building long-term shareholder value. Maya brings a phenomenal breadth of experiences, which we believe are highly complementary to the experience of our existing directors and Perspective’s management team. We believe she will be a strong steward for shareholders in helping advance our clinical programs and deliver on our goal of helping cancer patients with limited treatment options.”

“I am excited to join Perspective’s Board at such a pivotal time in the rapidly evolving radiopharma field, and to help demonstrate the promise of alpha emitting radioisotopes in the treatment of cancers throughout the body,” said Ms. Martinez-Davis. “I look forward to sharing

my insights and experience with the Perspective team, as the Company advances its three clinical-stage programs with potential to transform cancer treatment.”

Thijs Spoor, Perspective’s CEO, said, “I welcome the opportunity to work with Maya. Her commercial and clinical development experience in oncology will be a valuable resource for the Perspective team. We are at an exciting time in the Company’s history, as we are excited by the potential of our cutting-edge science to produce innovative new medicines that could improve patients’ lives.”

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company’s ability to build long-term shareholder value; the ability of alpha-emitting radioisotopes to treat cancers throughout the body; the Company’s ability to advance its clinical programs and develop medicines that could improve patients’ lives; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.

These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:

Annie J. Cheng, CFA

[email protected]

Russo Partners, LLC

Nic Johnson

[email protected]